Recently, Moulton and colleagues conducted a meta-analysis of 19 published RCTs (five of metformin, two of peroxisome proliferator-activated receptor (PPAR)-γ receptor agonists, two of incretin-based therapies, and one of insulin) on the effects of diabetes treatments on depressive symptoms. The gene discussed is INS; the disease is diabetes mellitus.